Trial Search Results

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase 2 trial studies how well ixazomib(MLN9708) works in treating patients with relapsed or refractory acute myeloid leukemia. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Bruno C. Medeiros

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):

Intervention(s):

  • Drug: ixazomib

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Diagnosis of relapsed or refractory AML of any French American British (FAB) subtype
   except M3 and NPM1 genetic mutation detected by molecular assay; AML patients treated
   at Stanford have NPM1 molecular mutation status checked routinely at time of diagnosis
   in a Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory

   - Male or female patients and no race-ethnic restrictions

   - Patients are unwilling, or who are determined to be medically unfit for or resistant
   to standard intensive induction chemotherapy; patients who are medically unfit will be
   determined by the treating primary hematologist and the principal investigator
   (including but not limited to evaluation of co-morbidities, and response and
   complications to previous AML treatment strategy)

   - Eastern Cooperative Oncology Group (ECOG) 0 to 2

   - Ability to understand and the willingness to sign a written informed consent document

   - Female patients who:

      - Are postmenopausal for at least 1 year before the screening visit, OR

      - Are surgically sterile, OR

      - If they are of childbearing potential, agree to practice 2 effective methods of
      contraception, at the same time, from the time of signing the informed consent
      form through 90 days after the last dose of study drug, AND

      - Must also adhere to the guidelines of any treatment-specific pregnancy prevention
      program, if applicable, OR

      - Agree to practice true abstinence when this is in line with the preferred and
      usual lifestyle of the subject; (periodic abstinence [eg, calendar, ovulation,
      symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
      of contraception)

   - Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
   to one of the following:

      - Agree to practice effective barrier contraception during the entire study
      treatment period and through 90 days after the last dose of study drug, OR

      - Must also adhere to the guidelines of any treatment-specific pregnancy prevention
      program, if applicable, OR

      - Agree to practice true abstinence when this is in line with the preferred and
      usual lifestyle of the subject; (periodic abstinence (eg, calendar, ovulation,
      symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
      of contraception)

   - Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN)

   - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN

   - Calculated creatinine clearance ≥ 30 mL/min

Exclusion Criteria:

   - Female patient who are lactating or have a positive serum pregnancy test during the
   screening period

   - Major surgery within 14 days before enrollment

   - Radiotherapy within 14 days before enrollment; if the involved field is small, 7 days
   will be considered a sufficient interval between treatment and administration of
   MLN9708

   - Known active and uncontrolled central nervous system (CNS) involvement of leukemia (a
   lumbar puncture does not need to be performed as a part of screening)

   - Have a significant uncontrolled infection active infection

   - Have other severe concurrent disease or serious organ dysfunction involving the heart,
   kidney, liver or other organ system that may place the patient at undue risk to
   undergo treatment including uncontrolled hypertension, uncontrolled cardiac
   arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial
   infarction within the past 6 months

   - Systemic treatment, within 14 days before the first dose of MLN9708, with strong
   inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2)
   (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P450, family
   3, subfamily A (CYP3A) (clarithromycin, telithromycin, itraconazole, voriconazole,
   ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin,
   rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo
   biloba or St. John's wort

   - Known ongoing or active systemic infection, active hepatitis B or C virus infection,
   or known human immunodeficiency virus (HIV) positive

   - Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
   absorption or tolerance of MLN9708 including difficulty

   - Diagnosed or treated for another malignancy within 2 years before study enrollment or
   previously diagnosed with another malignancy and have any evidence of residual
   disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are
   not excluded if they have undergone complete resection; this does not preclude
   previous diagnosis of acute myeloid leukemia or myelodysplastic syndrome

   - Patient has ≥ grade 3 peripheral neuropathy, or grade 2 with pain on clinical
   examination during the screening

   - Participation in other clinical trials, including those with other investigational
   agents not included in this trial, within 21 days of the start of this trial and
   throughout the duration of this trial

   - Known allergy to any of the study medications, their analogues, or excipients in the
   various formulations of any agent

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061
Not Recruiting